Oppenheimer Asset Management Inc. Has $2.42 Million Position in Inspire Medical Systems, Inc. (NYSE:INSP)

Oppenheimer Asset Management Inc. boosted its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 22.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 13,027 shares of the company’s stock after acquiring an additional 2,375 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Inspire Medical Systems were worth $2,415,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Wasatch Advisors LP increased its stake in Inspire Medical Systems by 1.6% in the third quarter. Wasatch Advisors LP now owns 1,323,470 shares of the company’s stock valued at $279,318,000 after purchasing an additional 20,481 shares in the last quarter. State Street Corp increased its stake in Inspire Medical Systems by 78.0% in the third quarter. State Street Corp now owns 1,049,784 shares of the company’s stock valued at $221,557,000 after purchasing an additional 459,990 shares in the last quarter. Janus Henderson Group PLC increased its stake in Inspire Medical Systems by 5.8% in the third quarter. Janus Henderson Group PLC now owns 502,609 shares of the company’s stock valued at $106,075,000 after purchasing an additional 27,374 shares in the last quarter. Geode Capital Management LLC increased its stake in Inspire Medical Systems by 0.7% in the third quarter. Geode Capital Management LLC now owns 483,654 shares of the company’s stock valued at $102,102,000 after purchasing an additional 3,128 shares in the last quarter. Finally, TimesSquare Capital Management LLC bought a new stake in Inspire Medical Systems in the fourth quarter valued at approximately $80,419,000. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

INSP has been the subject of several recent analyst reports. KeyCorp reaffirmed an “overweight” rating and issued a $234.00 target price (down previously from $236.00) on shares of Inspire Medical Systems in a research note on Friday, January 24th. Stifel Nicolaus lowered their price objective on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating for the company in a research report on Tuesday, January 21st. Robert W. Baird lowered their price objective on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating for the company in a research report on Tuesday, February 11th. Piper Sandler lowered their price objective on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $260.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday, February 11th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $228.82.

Inspire Medical Systems Trading Up 0.8 %

Inspire Medical Systems stock opened at $185.56 on Monday. The company has a market cap of $5.51 billion, a P/E ratio of 107.26, a price-to-earnings-growth ratio of 2.86 and a beta of 1.32. Inspire Medical Systems, Inc. has a 1-year low of $123.00 and a 1-year high of $257.40. The company has a fifty day simple moving average of $187.87 and a 200 day simple moving average of $193.12.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. On average, equities research analysts forecast that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, insider Randy Ban sold 25,584 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the sale, the insider now owns 7,259 shares in the company, valued at $1,332,026.50. This trade represents a 77.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CTO John Rondoni sold 583 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the sale, the chief technology officer now owns 10,424 shares of the company’s stock, valued at approximately $1,777,187.76. This represents a 5.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,225 shares of company stock worth $4,806,530 over the last quarter. 4.10% of the stock is currently owned by insiders.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.